Get the Stockscreener App
34.21
0.03%
0.010
Immunocore Holdings Plc Adr stock is traded at $34.21, with a volume of 194.69K.
It is up +0.03% in the last 24 hours and up +2.21% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$34.20
Open:
$34.02
24h Volume:
194.69K
Relative Volume:
0.38
Market Cap:
$1.74B
Revenue:
$413.05M
Net Income/Loss:
$-27.67M
P/E Ratio:
-60.98
EPS:
-0.561
Net Cash Flow:
$-30.75M
1W Performance:
+0.62%
1M Performance:
+2.21%
6M Performance:
+5.98%
1Y Performance:
+3.48%
1-Day Range:
$33.50
$34.39
1-Week Range:
$33.50
$35.19
52-Week Range:
$27.55
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
34.21 | 1.77B | 413.05M | -27.67M | -30.75M | -0.561 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-07-26 | Upgrade | UBS | Sell → Buy |
| Oct-31-25 | Initiated | Wells Fargo | Overweight |
| Sep-18-25 | Resumed | Guggenheim | Neutral |
| Aug-25-25 | Resumed | Jefferies | Buy |
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - MarketBeat
Q3 Earnings Forecast for Immunocore Issued By HC Wainwright - MarketBeat
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum - Yahoo Finance
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? - Yahoo Finance
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss - Yahoo Finance
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - Zacks Investment Research
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - sg.finance.yahoo.com
Immunocore Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Immunocore posts Q2 2026 revenue beat as EPS misses - Investing.com
Immunocore Holdings earnings missed by $0.03, revenue topped estimates - Investing.com
Immunocore set to report earnings ahead of pivotal trial data - Investing.com
Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stempoint Capital LP Purchases New Shares in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Eversept Partners LP Takes Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak - Yahoo! Finance Canada
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead - TradingView
Principal Financial Group Inc. Sells 139,306 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
IMCR News | IMMUNOCORE HOLDINGS PLC-ADR (NASDAQ:IMCR) - ChartMill
Is it a good idea to invest in Immunocore stock right now? - MSN
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib - TradingView
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push - TradingView
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - TradingView
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - TradingView
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - TradingView
Is it a Good Idea to Invest in Immunocore Stock Right Now? - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - TradingView
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - TradingView
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - TradingView
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - TradingView
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - TradingView
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - TradingView
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):